Tests two non-invasive ways to check liver scarring
Part of Digestive system clinical trials.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-alcohol-related fatty liver disease (NAFLD) shown on ultrasound or MRI, or by a specific ultrasound vibration measure
- You do not take certain fat-accumulating medications (like steroids, methotrexate, amiodarone, or tamoxifen)
- You drink less alcohol than the study allows (under 210 g/week for men or under 140 g/week for women)
- You do NOT have other chronic liver diseases like hepatitis B/C, hemochromatosis, autoimmune hepatitis, or similar conditions
- You are age 18 to 80, and can sign consent to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This study aims to develop better ways to measure how much fibrosis (scarring) in the liver improves after treatment for NASH (fatty liver with inflammation). If you have moderate to severe liver scarring from NASH, this research could help doctors track your condition more precisely, which may lead to more effective care.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Hear when a new NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.